<DOC>
	<DOC>NCT00984477</DOC>
	<brief_summary>The purpose of the study is to determine how quickly AZD5122 is absorbed into and cleared by the body when given to healthy, non smoking males at different dose levels. This is a 2 part study, in Part B a single group of subjects will be given both an oral dose and intravenous microdose of AZD5122 at a specialist unit. For part B there is no placebo treatment given.</brief_summary>
	<brief_title>Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Provision of signed and dated, written informed consent. Normal physical examination, laboratory values, blood pressure and pulse Healthy male caucasian subjects Subjects must not have any history of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with how drugs are absorbed, used or eliminated by the body. Subjects must not have abnormal blood or urine tests for hsCRP, circulating neutrophils, haematocrit, haemoglobin or renal function Subjects must not have crystals or more than a trace of blood in their urine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>healthy subjects</keyword>
	<keyword>AZD5122</keyword>
	<keyword>single oral dose</keyword>
	<keyword>phase 1</keyword>
	<keyword>Healthy volunteer phase 1 study</keyword>
</DOC>